176 related articles for article (PubMed ID: 34495306)
21. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA; Grover NS; Beaven AW; Lulla PD; Wu MF; Ivanova A; Wang T; Shea TC; Rooney CM; Dittus C; Park SI; Gee AP; Eldridge PW; McKay KL; Mehta B; Cheng CJ; Buchanan FB; Grilley BJ; Morrison K; Brenner MK; Serody JS; Dotti G; Heslop HE; Savoldo B
J Clin Oncol; 2020 Nov; 38(32):3794-3804. PubMed ID: 32701411
[TBL] [Abstract][Full Text] [Related]
23. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
Mei MG; Lee HJ; Palmer JM; Chen R; Tsai NC; Chen L; McBride K; Smith DL; Melgar I; Song JY; Bonjoc KJ; Armenian S; Nwangwu M; Lee PP; Zain J; Nikolaenko L; Popplewell L; Nademanee A; Chaudhry A; Rosen S; Kwak L; Forman SJ; Herrera AF
Blood; 2022 Jun; 139(25):3605-3616. PubMed ID: 35316328
[TBL] [Abstract][Full Text] [Related]
24. Nivolumab in the Treatment of Hodgkin Lymphoma.
Ansell SM
Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Lisano J; Wen R; Akyol A; Moskowitz AJ
Blood Adv; 2023 Sep; 7(18):5272-5280. PubMed ID: 37352266
[TBL] [Abstract][Full Text] [Related]
27. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
28. Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report.
Gunes AK; Demir I; Pehlivan M
J Oncol Pharm Pract; 2021 Mar; 27(2):509-512. PubMed ID: 32762294
[TBL] [Abstract][Full Text] [Related]
29. Where does PD-1 blockade fit in HL therapy?
Herrera AF
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
[TBL] [Abstract][Full Text] [Related]
30. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
Vasileiou S; Lulla PD; Tzannou I; Watanabe A; Kuvalekar M; Callejas WL; Bilgi M; Wang T; Wu MJ; Kamble R; Ramos CA; Rouce RH; Zeng Z; Gee AP; Grilley BJ; Vera JF; Bollard CM; Brenner MK; Heslop HE; Rooney CM; Leen AM; Carrum G
J Clin Oncol; 2021 May; 39(13):1415-1425. PubMed ID: 33507803
[TBL] [Abstract][Full Text] [Related]
31.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
32. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
[TBL] [Abstract][Full Text] [Related]
33. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Herrera AF; Moskowitz AJ; Bartlett NL; Vose JM; Ramchandren R; Feldman TA; LaCasce AS; Ansell SM; Moskowitz CH; Fenton K; Ogden CA; Taft D; Zhang Q; Kato K; Campbell M; Advani RH
Blood; 2018 Mar; 131(11):1183-1194. PubMed ID: 29229594
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
[TBL] [Abstract][Full Text] [Related]
35. Novel Therapies in the Treatment of Hodgkin Lymphoma.
Andrade-Gonzalez X; Ansell SM
Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
[TBL] [Abstract][Full Text] [Related]
36. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
37. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.
Manson G; Mear JB; Herbaux C; Schiano JM; Casasnovas O; Stamatoullas A; Deau B; Schmitt A; Garnier G; Regny C; Bouabdallah K; Moles-Moreau MP; Ghesquieres H; Tempescul A; Dulery R; Nicolas-Virelizier E; Delmer A; Borel C; Chauchet A; Damotte D; Dercle L; Brice P; Houot R;
Eur J Cancer; 2019 Jul; 115():47-56. PubMed ID: 31082693
[TBL] [Abstract][Full Text] [Related]
39. Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma.
Ogasawara R; Hashimoto D; Sugita J; Yamawaki F; Naka T; Mitsuhashi T; Takahashi S; Miyashita N; Okada K; Onozawa M; Matsuno Y; Teshima T
Int J Hematol; 2020 Mar; 111(3):475-479. PubMed ID: 31538325
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
Onizuka M; Kojima M; Matsui K; Machida S; Toyosaki M; Aoyama Y; Kawai H; Amaki J; Hara R; Ichiki A; Ogawa Y; Kawada H; Nakamura N; Ando K
Int J Hematol; 2017 Jul; 106(1):141-145. PubMed ID: 28097534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
